lobbying_activities: 1703039

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1703039	208f33c0-5822-4bdb-b65e-0c57cbbfc5da	Q2	APOTEX CORP.	310973	APOTEX CORP.	2015	second_quarter	PHA	HR 6 - The 21st Century Cures Act, provisions relating to the discovery, approval and manufacturing of pharmaceuticals; FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; HR 2841 - The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S 1137 - The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity periods; Federal policy relating to International Nonproprietary Names for biosimilars; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, The Patient Protection and Affordable Care Act; and Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, provisions in Title 3, Fees Relating to Generic Drugs.	HOUSE OF REPRESENTATIVES,SENATE		260000	0	0	2015-07-17T12:44:33.497000-04:00